{
    "eid": "2-s2.0-84979503381",
    "title": "First-line erlotinib therapy until and beyond response evaluation criteria in solid tumors progression in Asian patients with epidermal growth factor receptor mutation-positive non-small-cell lung cancer the ASPIRATION study",
    "cover-date": "2016-03-01",
    "subject-areas": [
        {
            "$": "Cancer Research",
            "@code": "1306"
        },
        {
            "$": "Oncology",
            "@code": "2730"
        }
    ],
    "keywords": [],
    "authors": [
        "Keunchil Park"
    ],
    "citedby-count": 206,
    "ref-count": 24,
    "ref-list": [
        "Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non-Small-Cell Lung Cancer to Gefitinib",
        "EGFR mutations in lung, cancer: Correlation with clinical response to gefitinib therapy",
        "Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma",
        "First-SIGNAL: First-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung",
        "Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial",
        "Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR",
        "Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study",
        "The impact of EGFR T790M mutations and BIM mRNA expression on outcome in patients with EGFR-Mutant NSCLC treated with erlotinib or chemotherapy in the randomized phase III EURTAC trial",
        "Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations",
        "Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer",
        "Reporting results of cancer treatment",
        "New guidelines to evaluate the response to treatment in solid tumors",
        "New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)",
        "The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP",
        "Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus",
        "J Clin Oncol",
        "Epidermal growth factor receptor tyrosine kinase inhibitors beyond progressive disease: A retrospective analysis for Japanese patients with activating EGFR mutations",
        "NCCN Guidelines Version 1.2015. Non-Small Cell Lung Cancer. National Comprehensive Cancer Network Website",
        "Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC",
        "The EGFR T790M mutation in acquired resistance to an irreversible second-generation EGFR inhibitor",
        "Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): A phase 3 randomised trial",
        "Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: Distinct natural history of patients with tumors harboring the T790M mutation",
        "Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): A randomised, double-blind trial",
        "Detection and dynamic changes of EGFR mutations from circulating tumor DNA as a predictor of survival outcomes in NSCLC Patients treated with first-line intercalated erlotinib and chemotherapy"
    ],
    "affiliation": [
        {
            "affiliation-city": "Hong Kong",
            "affilname": "Chinese University of Hong Kong",
            "affiliation-country": "Hong Kong"
        },
        {
            "affiliation-city": "Seoul",
            "affilname": "The Catholic University of Korea Seoul St. Mary's Hospital",
            "affiliation-country": "South Korea"
        },
        {
            "affiliation-city": "Seongnam",
            "affilname": "Seoul National University Bundang Hospital",
            "affiliation-country": "South Korea"
        },
        {
            "affiliation-city": "Taoyuan",
            "affilname": "Chang Gung University College of Medicine",
            "affiliation-country": "Taiwan"
        },
        {
            "affiliation-city": "Taipei",
            "affilname": "National Taiwan University Hospital",
            "affiliation-country": "Taiwan"
        },
        {
            "affiliation-city": "Taipei",
            "affilname": "National Yang-Ming University Taiwan",
            "affiliation-country": "Taiwan"
        },
        {
            "affiliation-city": "Taipei",
            "affilname": "Chang Gung Memorial Hospital",
            "affiliation-country": "Taiwan"
        },
        {
            "affiliation-city": "Bangkok",
            "affilname": "Chulalongkorn University",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Suwon",
            "affilname": "SKKU School of Medicine",
            "affiliation-country": "South Korea"
        },
        {
            "affiliation-city": "Taipei",
            "affilname": "Taipei Veterans General Hospital",
            "affiliation-country": "Taiwan"
        },
        {
            "affiliation-city": "Basel",
            "affilname": "F. Hoffmann-La Roche AG",
            "affiliation-country": "Switzerland"
        },
        {
            "affiliation-city": "Seoul",
            "affilname": "University of Ulsan College of Medicine",
            "affiliation-country": "South Korea"
        },
        {
            "affiliation-city": "Sydney",
            "affilname": "Roche Products Pty Ltd",
            "affiliation-country": "Australia"
        }
    ],
    "funding": []
}